Prodia had the opportunity to attend the Singapore Drug Information Association (DIA) 2025 and Asia DIA 2025 conferences. Held in Singapore, these events brought together industry professionals, researchers, and regulatory experts to share knowledge and insights on the latest developments in drug development, clinical trials, and regulatory affairs.

The conferences featured a range of sessions, including keynote presentations, panel discussions, and workshops, covering topics such as innovative trial designs, real-world evidence, and regulatory updates. Prodia team had the chance to engage with speakers and attendees, learning about the latest trends and best practices in the industry.

Attending these conferences provided valuable opportunities for networking, professional development, and staying up-to-date on the latest industry developments.

The IASMED 2025 Scientific Seminar “Moving Forward: Indonesian Clinical Trial” was held on Saturday, January 18, 2025, by Indonesia’s clinical trial association, The Indonesian Association for The Study of Medicines (IASMED).

This seminar is aimed to provide IASMED members to update information regarding clinical trial sites in order to improve the quality and quantity of clinical trials in Indonesia, especially multi-regional clinical trials (MRCT). There are two sessions on this scientific seminar. The first session consists of 4 speakers that are apt. Indri Rooslamiati, M.Sc as the Head of BB Binomika, Prof. dr. Taruna Ikrar, M.Biomed., Ph.D – Head of BPOM, Prof. Young Joo Par as  Vice President DIA Korea, Singapore, and Southeast Asia and Dra. Endang W. Hoyaranda as the head of IASMED. The second session is a panel discussion with the clinical trial stakeholders.  One of the main speaker is Prof. dr. Taruna Ikrar, M.Biomed., Ph.D – Head of BPOM. He said that BPOM will continue to supervise the clinical trial center’s infrastructure and personnel and keep fostering collaboration and integration among academia, business, and governance. There is also a networking session on this seminar where IASMED members can meet representatives from Clinical Research Unit of many hospitals and other clinical trials collaborators.

In this event, also was attended bt  clinical trial professionals such as Prof. Dr. Rianto Setiabudy, Prof. Arini Setiawati, and Prof. Young Joo Park, Vice President of the Drug Information Association (DIA) Korea, Singapore, and Southeast Asia, Indri Rooslamiati, M.Sc., Apt. Head of BB Binomika, CRUs, sponsors, global and local CROs.

In addition to the scientific agenda,during this eventalso celebrated the election of the IASMED chairs, including the new IASMED committee chairs and IASMED supervisory board chair.  May IASMED continued success and contribute more to enhancing the quality and quantity of clinical trials in Indonesia.

Prodia the CRO, believes that this marked as an excellent time for clinical trials in Indonesia. Prodia the CRO is a Contract Research Organization (CRO) based in Indonesia which provides GCP-based Clinical Trial supports through our integrated and wide range of services. Prodia the CRO has accumulated many experiences providing services to local as well as multinational companies with commitment to reach quality through qualified and dedicated resources. It provides customers in GCP trials with competitive costs, firm timeliness, and high compliance to ICH-GCP guidelines(CDF).

Prodia The CRO team, represented by Erizal Sugiono (Director) and Rosalia Napitupulu (Business Development Manager), attended a forum group discussion initiated by Badan Pengawas Obat dan Makanan (BPOM) on October 31, 2024, held in Fairmont Hotel, Jakarta.

The topic of this discussion was “A Blueprint for Innovation Success: Optimal Quality of Clinical Trial Centers and Practitioners”. The event was held as a follow up of the Cooperation Agreement between BPOM, the Ministry of Health (MoH), and the National Research and Innovation Agency (BRIN) which was signed on July 19, 2024.

The scope of cooperation agreement includes the coordination in the clinical research approval, clinical research center mapping and guidance, clinical research registry, and improvement of clinical research practitioners competency. It is hoped that by the synergy in national policies related to research development, and utilization of science and technology, as well as clinical trial services and supervision, can be achieved.

The roles and duties of BPOM in clinical trials were described by Ria Christine Siagian, Director of Drug Registration, BPOM. The responsibilities include assessing applications for approval of clinical trial implementation (PPUK), monitoring and evaluating the conducting of clinical trials, mapping clinical trial centers, providing training in good clinical trial methods (CUKB), and disseminating PPUK data and inspection findings.

According to Indri Rooslamiati (the representative of the Directorate General of Health Services, MoH), the role of the MoH in improving the quality and safety of clinical trial implementation in Indonesia paved by the establishment of Indonesia Clinical Research Center (INA-CRC), which is a one-stop solution for the implementation of clinical research. The INA-CRC initiative includes transparency of procedures and digitalization of the Material Transfer Agreement (MTA) submission, revamping clinical study that registry through the Indonesia Clinical study Registry (INA-CRR) website, and the establishment of National Ethics Committee. The data between clinical trial approval (BPOM) will be interfaced with INA-CRC.

According to Ramatun Anggraini Kiemas (Deputy for Research and Innovation Facilitation—BRIN), BRIN is in charge of bolstering and coordinating institutions through the creation and accreditation of the Health Ethics Commission, financing the conduct of pre-clinical and clinical trials, and overseeing and carrying out clinical trials, enhancing human resource competency, and advancing clinical trial implementation.

 

Prodia the CRO, believes that this cooperation will result in a positive impact on clinical trials in Indonesia. This cooperation has the chance to increase both the number and quality of clinical studies while guaranteeing that they are carried out in a transparent, ethical, and GCP standard. Furthermore, we believe that this synergy approach will make Indonesia more appealing for clinical trials in global markets.

Prodia the CRO is a Contract Research Organization (CRO) based in Indonesia which provides GCP-based Clinical Trial supports through our integrated and wide range of services. Prodia the CRO has accumulated many experiences providing services to local as well as multinational companies with commitment to reach quality through qualified and dedicated resources. It provides customers in GCP trials with competitive costs, firm timeliness, high compliance to ICH-GCP guidelines.

The Prodia CRO team attended the launch of the Indonesia Clinical Research Center (INA-CRC) which was inaugurated by the Ministry of Health of the Republic of Indonesia at the Eijkman Building, dr. Cipto Mangunkusumo Hospital (RSCM) on October 16, 2024. The INA-CRC launch was attended by Prodia the CRO’s team, represented by Erizal Sugino (Director) and  Ida Paulina (SMO Manager).

This is a significant leap as part of the transformation of clinical research in Indonesia. In order to facilitate and coordinate Clinical Research Units (CRU) in all Indonesian hospitals, INA CRC was founded in accordance with the Decree of the Minister of Health of the Republic of Indonesia No. HK.01.07/MENKES/1458/2023 about the Implementation of Clinical Research in Hospitals.

INA-CRC will boost Indonesia as regional clinical research hub whileplaya a role in the advancement of the transformation of clinical research in Indonesia. INA CRC is dedicated to improving national competitiveness in the health sector, driving health innovation, and emerging as a major force in international clinical research. Additionally, it will make Indonesia more competitive and appealing to both domestic and foreign enterprises as a clinical research site. The Indonesian Minister of Health said that INA CRC is the missing piece of clinical trial and health innovation in Indonesia.

Furthermore, Prodia the CRO believes that clinical trials in Indonesia may be transformed and synergized with a strong commitment from every stakeholder. According to Dr. Ida Paulina, Site Management Manager of Prodia the CRO, INA CRC is a collective aspiration that has now come into reality and is anticipated to improve clinical research unit among hospitals in Indonesia. INA CRC is expected to contribute significantly to the advancement of medical innovation in Indonesia. Prodia the CRO gives its utmost commitment working with INA CRC in delivering highest quality for clinical trials through clinical research unit establishment in hospitals across Indonesia. As the first actions after its inauguration, INA-CRC launch the initiative to transform clinical trial implementation in Indonesian. Those are the re-branding Indonesian clinical registry and simplified material transfer agreement (MTA) submission. With this transformation, sponsors will have certainty in both timeline and approval process.

About Prodi the CRO. Prodia the CRO is a Contract Research Organization (CRO) based in Indonesia which provides GCP-based Clinical Trial supports through our integrated and wide range of services. Prodia the CRO has accumulated many experiences providing services to local as well as multinational companies with commitment to reach quality through qualified and dedicated resources. It provides customers in GCP trials with competitive costs, firm timeliness, high compliance to ICH-GCP guidelines.